Dansylated analogues of the opioid peptide [Dmt1]DALDA:: in vitro activity profiles and fluorescence parameters

被引:0
|
作者
Berezowska, I
Lemieux, C
Chung, NN
Zelent, B
Schiller, PW
机构
[1] Clin Res Inst Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ H2W 1R7, Canada
[2] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA
关键词
Dmt(1)]DALDA; opioid peptides; fluorescent opioid peptide analogues; fluorescence spectroscopy; fluorescence quantum yield; opioid activity profile in vitro;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dansylated analogues of the potent and selective mu opioid peptide agonist [Dmt(1)]DALDA (H-Dmt-D-Arg-Phe Lys-NH2; Dmt = 2',6'-dimethyltyrosine) were prepared either by substitution of N-beta-dansyl-alpha,beta-diaminopropionic acid or N-epsilon-dansyl-lysine for Lys(4), or by attachment of a dansyl group to the C-terminal carboxamide function via a linker. All three analogues displayed high mu agonist potency in vitro and the C-terminally dansylated one retained significant mu receptor selectivity. The three analogues showed interesting differences in their fluorescence emission maxima and quantum yields, indicating that the dansyl group in two of them was engaged in intramolecular hydrophobic interactions. These dansylated [Dmt(1)]DALDA analogues represent valuable tools for binding studies, cellular uptake and intracellular distribution studies, and tissue distribution studies.
引用
收藏
页码:107 / 113
页数:7
相关论文
共 25 条
  • [1] Highly potent fluorescent analogues of the opioid peptide [Dmt1]DALDA
    Berezowska, I
    Chung, NN
    Lemieux, C
    Zelent, B
    Szeto, HH
    Schiller, PW
    [J]. PEPTIDES, 2003, 24 (08) : 1195 - 1200
  • [2] [Dmt1] DALDA analogues with enhanced μ opioid agonist potency and with a mixed μ/κ opioid activity profile
    Bai, Longxiang
    Li, Ziyuan
    Chen, Jiajia
    Chung, Nga N.
    Wilkes, Brian C.
    Li, Tingyou
    Schiller, Peter W.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (07) : 2333 - 2338
  • [3] Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the Mu Opioid Receptor
    Dumitrascuta, Maria
    Bermudez, Marcel
    Ballet, Steven
    Wolber, Gerhard
    Spetea, Mariana
    [J]. MOLECULES, 2020, 25 (09):
  • [4] Synthesis and in vitro opioid activity profiles of DALDA analogues
    Schiller, PW
    Nguyen, TMD
    Berezowska, I
    Dupuis, S
    Weltrowska, G
    Chung, NN
    Lemieux, C
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (10) : 895 - 901
  • [5] [Dmt1]DALDA analogues modified with tyrosine analogues at position 1
    Cai, Yunxin
    Lu, Dandan
    Chen, Zhen
    Ding, Yi
    Chung, Nga N.
    Li, Tingyou
    Schiller, Peter W.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (15) : 3629 - 3631
  • [6] Differential Analgesic Effects of a Mu-Opioid Peptide, [Dmt1]DALDA, and Morphine
    Shimoyama, Megumi
    Szeto, Hazel H.
    Schiller, Peter W.
    Tagaito, Yugo
    Tokairin, Hideyuki
    Eun, Chong Moon
    Shimoyama, Naohito
    [J]. PHARMACOLOGY, 2009, 83 (01) : 33 - 37
  • [7] Pharmacological characterization of the dermorphin analog [Dmt1]DALDA, a highly potent and selective μ-opioid peptide
    Neilan, CL
    Nguyen, TMD
    Schiller, PW
    Pasternak, GW
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 419 (01) : 15 - 23
  • [8] Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA
    Szeto, HH
    Soong, Y
    Wu, DL
    Qian, XX
    Zhao, GM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (02): : 696 - 702
  • [9] Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at μ, δ, and κ opioid receptors
    Zhao, GM
    Qian, XX
    Schiller, PW
    Szeto, HH
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (03): : 947 - 954
  • [10] The cardiovascular and renal effects of the potent and highly selective μ opioid agonist [Dmt1]DALDA
    Gutkowska, J
    Mukaddam-Daher, S
    Jankowski, M
    Schiller, PW
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 (06) : 651 - 658